8 Papers
Adi Mor is an academic researcher from Tel Aviv Sourasky Medical Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Role of Naturally Occurring CD4+CD25+ Regulatory T Cells in Experimental Atherosclerosis
Adi Mor,David Planer,Galia Luboshits,Arnon Afek,Shula Metzger,Tova Chajek-Shaul,Gad Keren,Jacob George +7 more
TL;DR: CD4+CD25+ Tregs may play a protective role in the progression of atherosclerosis and could be considered a therapeutic tool if results from human studies can solidify observations in murine models.
362
Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes.
TL;DR: In this paper, the authors have hypothesized that peripheral numbers and function of Tregs would be deranged in patients with acute coronary syndromes (ACS), and they have evaluated by FACS employing labelled antibodies to CD4 and CD25.
320
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells
Karin Mausner-Fainberg,Galia Luboshits,Adi Mor,Sophia Maysel-Auslender,Ardon Rubinstein,Gad Keren,Jacob George +6 more
TL;DR: In conclusion, statins appear to significantly influence the peripheral pool of Tregs in humans, which may shed light on the mechanisms governing the plaque stabilizing properties of statins.
252
CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis.
Raanan Greenman,Michal Segal-Salto,Neta Barashi,Ophir Hay,Avi Katav,O Levi,Ilan Vaknin,Revital Aricha,Tom Snir,Inbal Mishalian,Devorah Olam,Johnny Amer,A. Salhab,Rifaat Safadi,Yaakov Maor,Palak J. Trivedi,Christopher J. Easton,Francesca Saffioti,Andrew Hall,Massimo Pinzani,Douglas Thorburn,Amnon Peled,Adi Mor +22 more
TL;DR: In this paper , the role of CCL24 in primary sclerosing cholangitis (PSC) and evaluated the potential therapeutic effect of blocking CCL 24 in this disease.
Ab0808 a proof of biological concept trial of cm101 to target ccl24 in systemic sclerosis: a biomarker informed, precision medicine approach
Francesco Del Galdo,D. Khanna,Chris Crater,Revital Aricha,Jessica L. Lawler,Adi Mor,Ilan Vaknin,Melissa Frankel,Marco Matucci-Cerinic +8 more
TL;DR: In this article , the authors proposed a biomarker enriched clinical trial to evaluate the biological activity of CM101 in patients with Systemic Sclerosis, across limited and cutaneous subsets, with comprehensive safety and efficacy assessments.